The Role of Open Access in Reducing Waste in Medical Research by Glasziou, Paul
Bond University
Research Repository
The Role of Open Access in Reducing Waste in Medical Research
Glasziou, Paul
Published in:
PLoS Medicine
DOI:
10.1371/journal.pmed.1001651
Published: 01/01/2014
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Glasziou, P. (2014). The Role of Open Access in Reducing Waste in Medical Research. PLoS Medicine, 11(5),
[e1001651]. https://doi.org/10.1371/journal.pmed.1001651
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 09 Oct 2020
Editorial
The Role of Open Access in Reducing Waste in Medical
Research
Paul Glasziou*
Bond University, Robina, Australia
Twenty years ago an editorial by Doug
Altman in the BMJ [1], ‘‘The Scandal of
Poor Medical Research’’, decried the poor
design and reporting of research, stating
that ‘‘huge sums of money are spent
annually on research that is seriously flawed
through the use of inappropriate designs,
unrepresentative samples, small samples,
incorrect methods of analysis, and faulty
interpretation’’. Since then, change has
been gradual, while the list of problems
has lengthened, and documentation of their
magnitude has accumulated. Recent years,
however, have seen a crescendo of concern.
Public awareness has been accelerated with
the publication of Ben Goldacre’s Bad
Pharma [2], which clearly articulated the
problems posed by biased non-publication
and reporting of pharmaceutical research.
Wider awareness of these issues helped
spark the AllTrials campaign (http://www.
alltrials.net/), which asks for ‘‘all trials
registered; all results reported’’. Of course,
the problems of poor design and reporting,
as well as selective non-publication, extend
well beyond drug trials to most areas of
research: drug and non-drug, basic and
applied, interventional and observational,
animal and human. A 2009 paper in The
Lancet [3] estimated that three problems—
flawed design, non-publication, and poor
reporting—together meant over 85% of
research funds were wasted, implying a
global total loss of over US$100 billion per
year. This year, a follow-up series [4] more
extensively documented this wastage, con-
firming the earlier estimate, but adding
details and a series of more explicit
recommendations for action.
The waste sounds bad, but the reality is
worse. The estimate that 85% of research is
wasted referred only to activities prior to the
point of publication. Much waste clearly
occurs after publication: from poor access,
poor dissemination, and poor uptake of
the findings of research. The develop-
ment of open access to research [5] is
important to reduce this post-publication
waste. Poor access—including paywalls, re-
strictions on re-publication and re-use, etc.—
limits both researcher-to-researcher and
researcher-to-clinician communications. As
PLOS Medicine editorial leaders pointed out in
a PubMed Commons response to the Lancet
series [6], open access is more than free access
and includes ‘‘free, immediate access online;
unrestricted distribution and re-use rights in
perpetuity for humans and technological
applications; author(s) retains rights to attri-
bution; papers are immediately deposited in a
public online archive, such as PubMed
Central’’ [7]. Globally, the most important
access problem is arguably due to language
barriers, and with the growth of research in
non-English-speaking countries, particularly
China, this problem is likely to grow.
Language barriers make even free-access
research unusable, but by eliminating restric-
tions on re-publication and re-use, open
access can at least reduce barriers to
translation.
Solving the problems of pre-publication
waste and post-publication access could
hugely accelerate medical research. Even
the complete solution of these problems,
however, would be insufficient to close the
research–practice gap. Paradoxically, the
plethora of research is itself a barrier to its
use. A recent analysis of trials and reviews
by specialty found an unmanageable scatter
of research [8]. For example, in neurology
the annual output was 2,770 trials across
896 journals, and 547 systematic reviews
across 292 journals. So, in addition to
access, clever systems of synthesis, filtering,
findability, and usability are needed if the
users of research are to cope with this
information deluge [9]. The enormous
marketing budgets of pharmaceutical com-
panies demonstrate the importance they
place on investing resources in getting the
message of their research to decision
makers. Unfortunately, little such invest-
ment is made in non-commercial research,
and this research is consequently neglected.
This concern has led to the development
of different approaches given names such
as ‘‘evidence-based medicine’’, ‘‘know-
ledge translation’’, and ‘‘implementation
science’’.
To get full value from research invest-
ment, we need to reduce both the annual
US$100 billion of pre-publication (re-
search production) waste and the unquan-
tified cost of post-publication (research
dissemination) barriers (Figure 1). Open
access will not in itself fix the problems of
poor research question selection, poor
study design, selective non-publication, or
poor or biased reporting, but these can be
ameliorated considerably through appro-
priate editorial policies and peer review
processes. Open-access medical journals
must maintain particularly high standards
for these processes in order to avoid
merely increasing access to a biased
selection of (often flawed) research. At
the same time, improving research quality
but keeping access restricted would mean
continued waste in the use and uptake of
good science.
‘‘As the system encourages poor
research,’’ wrote Altman in 1994 [1],
‘‘it is the system that should be changed.
We need less research, better research,
and research done for the right rea-
sons.’’ To that must be added a need for
research that is communicated effective-
ly to those who need it. If over a 100
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billion dollars of medical research mon-
ey were being wasted by corruption, the
public and political outcry would be
overwhelming. That resources of this
magnitude are being wasted through
incompetence and inattention should
be seen as a similar scandal. Badly
designed and poorly thought through
systems of research and dissemination
subtract massively from global human
health: they demand attention—and
action.
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